# China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

> **NCT06868654** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 72 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Belantamab mafodotin
- **DRUG:** Daratumumab
- **DRUG:** Bortezomib
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT06868654
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-07-28
- **Primary completion:** 2024-04-03
- **Final completion:** 2028-06-30
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06868654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06868654, "China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-09-14 from https://api.ai-analytics.org/clinical/NCT06868654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*